Shillong Herald

DUB Inhibitors Competitive Landscape, Pipeline Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

 Breaking News
  • No posts were found

DUB Inhibitors Competitive Landscape, Pipeline Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

May 11
19:28 2023
DUB Inhibitors Competitive Landscape, Pipeline Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, DUB Inhibitors Competitive Landscape constitutes 7+ key companies continuously working towards developing 8+ DUB Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The DUB Inhibitors Competitive Landscape report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

DUB Inhibitors Competitive Landscape Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the DUB Inhibitors Market.

 

Some of the key takeaways from the DUB Inhibitors Competitive Landscape Report:

  • Companies across the globe are diligently working toward developing novel DUB Inhibitors treatment therapies with a considerable amount of success over the years. 
  • DUB Inhibitors companies working in the treatment market are USP7 Ubiquigent, Carmot Therapeutics, Molecure, Mission Therapeutics, Tango Therapeutics, Mission Therapeutics, KSQ Therapeutics, Cothera Bioscience, and others, are developing therapies for the DUB Inhibitors treatment 
  • Emerging DUB Inhibitors therapies such as – Research program, Small molecules, OAT-4828, MTX325, TNG348, MTX652, KSQ-427, PC-002, and others are expected to have a significant impact on the DUB Inhibitors market in the coming years.
  • In June 2021, The US Food and Drug Administration (FDA) has given the go-ahead for PC-002 to be used in a global multi-center phase II clinical trial for the treatment of high-grade B-cell lymphoma that is resistant or refractory to first-line and second-line therapies, according to Cothera Bioscience
  • In December 2022, To ascertain the safety and effectiveness of sepantronium bromide (SepB) in adult patients with relapsed or refractory high-grade B-cell lymphoma, Cothera Biosciences started a multi-center Phase 2 research. At each dose level for SepB, cohorts of three patients will be enrolled, with the potential for expansion to six patients to evaluate toxicity

 

DUB Inhibitors Overview

The UPS, or ubiquitin-proteasome system, is made up in large part of deubiquitinating enzymes (DUBs). DUBs’ primary function is the targeted removal of ubiquitin from substrates. DUBs serve significant roles in a variety of cellular processes by assisting with the recycling, localisation, activation/deactivation, and localization of several regulatory proteins.

 

Get a Free Sample PDF Report to know more about DUB Inhibitors Competitive Landscape Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/dub-inhibitors-market

 

Emerging DUB Inhibitors Drugs Under Different Phases of Clinical Development Include:

  • Research program: USP7 Ubiquigent
  • Small molecules: Carmot Therapeutics
  • OAT-4828: Molecure
  • MTX325: Mission Therapeutics
  • TNG348: Tango Therapeutics
  • MTX652: Mission Therapeutics
  • KSQ-4279: KSQ Therapeutics
  • PC-002: Cothera Bioscience

 

DUB Inhibitors Competitive Landscape Therapeutics Assessment

  • DUB Inhibitors Assessment by Product Type
  • DUB Inhibitors By Stage and Product Type
  • DUB Inhibitors Assessment by Route of Administration
  • DUB Inhibitors By Stage and Route of Administration
  • DUB Inhibitors Assessment by Molecule Type
  • DUB Inhibitors by Stage and Molecule Type

 

DelveInsight’s DUB Inhibitors Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further DUB Inhibitors product details are provided in the report. Download the DUB Inhibitors Competitive Landscape report to learn more about the emerging DUB Inhibitors therapies

 

Some of the key companies in the DUB Inhibitors Therapeutics Market include:

Key companies developing therapies for DUB Inhibitors are – C4 Therapeutics, Arvinas, Genentech, Inc., AbbVie Inc., Merck & Co., Inc., Celgene Corporation, Novartis International AG, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, AstraZeneca PLC, Vertex Pharmaceuticals Incorporated, Eli Lilly and Company, Pfizer Inc., Sanofi, Janssen Pharmaceuticals, Inc., Astex Pharmaceuticals, Calico Life Sciences LLC, Forma Therapeutics, and others.

 

DUB Inhibitors Competitive Landscape Analysis:

The DUB Inhibitors Competitive Landscape report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of DUB Inhibitors with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for DUB Inhibitors Treatment.
  • DUB Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • DUB Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the DUB Inhibitors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about DUB Inhibitors drugs and therapies

 

DUB Inhibitors Competitive Landscape Market Drivers

  • Novel candidates for target-directed drug development, DUBs play major roles in diverse cellular-processes are some of the important factors that are fueling the DUB Inhibitors Market.

 

DUB Inhibitors Competitive Landscape Market Barriers

  • However, lack of in-depth studies to understand their natural regulatory mechanisms, inhibitors developed could have severe adverse effects by affecting non-target pathways and other factors are creating obstacles in the DUB Inhibitors Market growth.

 

Scope of DUB Inhibitors Competitive Landscape Drug Insight    

  • Coverage: Global
  • Key DUB Inhibitors Companies: USP7 Ubiquigent, Carmot Therapeutics, Molecure, Mission Therapeutics, Tango Therapeutics, Mission Therapeutics,  KSQ Therapeutics, Cothera Bioscience, and others
  • Key DUB Inhibitors Therapies: Research program, Small molecules, OAT-4828, MTX325, TNG348, MTX652, KSQ-427, PC-002, and others
  • DUB Inhibitors Therapeutic Assessment: DUB Inhibitors current marketed and DUB Inhibitors emerging therapies
  • DUB Inhibitors Market Dynamics: DUB Inhibitors market drivers and DUB Inhibitors market barriers 

 

Request for Sample PDF Report for DUB Inhibitors Competitive Landscape Assessment and clinical trials

 

Table of Contents

1

DUB Inhibitors Report Introduction

2

DUB Inhibitors Executive Summary

3

DUB Inhibitors Overview

4

DUB Inhibitors- Analytical Perspective In-depth Commercial Assessment

5

DUB Inhibitors Competitive Landscape Therapeutics

6

DUB Inhibitors Late Stage Products (Phase II/III)

7

DUB Inhibitors Mid Stage Products (Phase II)

8

DUB Inhibitors Early Stage Products (Phase I)

9

DUB Inhibitors Preclinical Stage Products

10

DUB Inhibitors Therapeutics Assessment

11

DUB Inhibitors Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

DUB Inhibitors Key Companies

14

DUB Inhibitors Key Products

15

DUB Inhibitors Unmet Needs

16 

DUB Inhibitors Market Drivers and Barriers

17

DUB Inhibitors Future Perspectives and Conclusion

18

DUB Inhibitors Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles